What Researchers Did
Researchers conducted a randomized trial to evaluate the effect of early hyperbaric oxygen therapy on quality of life and side effects in 19 patients with oropharyngeal and nasopharyngeal cancer after radiotherapy.
What They Found
Patients receiving hyperbaric oxygen therapy (HBOT) showed significantly better quality of life scores across all measured items compared to those who did not. Specifically, HBOT significantly improved swallowing (p = 0.011), dry mouth (p = 0.009), sticky saliva (p = 0.01), eating in public (p = 0.027), and pain in mouth (p < 0.0001).
What This Means for Canadian Patients
Canadian patients undergoing radiotherapy for oropharyngeal and nasopharyngeal cancers might experience improved quality of life and reduced side effects with early hyperbaric oxygen therapy. This could lead to better post-treatment recovery and overall well-being for those affected by these cancers.
Canadian Relevance
This study has no direct Canadian connection as it was not conducted in Canada, nor did it involve Canadian researchers or participants.
Study Limitations
A significant limitation of this study is its very small sample size of only 19 patients, making these early results preliminary.